Literature DB >> 9377812

A bi-allelic tetranucleotide repeat in the promoter of the human inducible nitric oxide synthase gene.

R Bellamy1, A V Hill.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9377812     DOI： 10.1111/j.1399-0004.1997.tb02544.x

Source DB:  PubMed          Journal:  Clin Genet        ISSN： 0009-9163            Impact factor:   4.438


× No keyword cloud information.
  5 in total

1.  Inducible nitric oxide synthase promoter polymorphism affords protection against cognitive dysfunction after carotid endarterectomy.

Authors:  Gene T Yocum; John G Gaudet; Susie S Lee; Yaakov Stern; Lauren A Teverbaugh; Robert R Sciacca; Charles W Emala; Donald O Quest; Paul C McCormick; James F McKinsey; Nicholas J Morrissey; Robert A Solomon; E Sander Connolly; Eric J Heyer
Journal:  Stroke       Date:  2009-03-12       Impact factor: 7.914

2.  Critique of "chromosome 17 and the inducible nitric oxide synthase gene in human essential hypertension" by Rutherford et al., Human Genetics, published online September 2001.

Authors:  Brian J Morris
Journal:  Hum Genet       Date:  2001-12-13       Impact factor: 4.132

Review 3.  Inducible nitric oxide synthase in human diseases.

Authors:  K D Kröncke; K Fehsel; V Kolb-Bachofen
Journal:  Clin Exp Immunol       Date:  1998-08       Impact factor: 4.330

4.  Inducible nitric oxide synthase polymorphism is associated with the increased risk of differentiated gastric cancer in a Japanese population.

Authors:  Yasuyuki Goto; Takafumi Ando; Mariko Naito; Hidemi Goto; Nobuyuki Hamajima
Journal:  World J Gastroenterol       Date:  2006-10-21       Impact factor: 5.742

5.  Polymorphisms in oxidative pathway related genes and susceptibility to inflammatory bowel disease.

Authors:  Nezha Senhaji; Sellama Nadifi; Younes Zaid; Aurora Serrano; Daniel Arturo Leon Rodriguez; Nadia Serbati; Mehdi Karkouri; Wafaa Badre; Javier Martín
Journal:  World J Gastroenterol       Date:  2017-12-21       Impact factor: 5.742
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.